SCHEMBL21883574

SCHEMBL21883574

CCCCCCc1nccc(C)c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 4/20 0.46
NOS3 P29474 3/20 0.46
DHFR P00374 1/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTR2A P28223 1/20 0.38
KCNH2 Q12809 1/20 0.38
TLR8 Q9NR97 4/20 0.38
TLR7 Q9NYK1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8713669 0.93 NOS2 (0.49) NOS2NOS3ALDH1A1KDM4EMEN1
SCHEMBL21567686 0.85 NOS2 (0.56) NOS2NOS3ALDH1A1KDM4EMEN1
SCHEMBL28182429 0.82 NOS2 (0.41) NOS2NOS3DHFRALDH1A1KDM4E
SCHEMBL31282524 0.82 NOS2 (0.41) NOS2NOS3DHFRALDH1A1KDM4E
SCHEMBL28323117 0.82 NOS2 (0.41) NOS2NOS3DHFRALDH1A1KDM4E
SCHEMBL31283581 0.82 NOS2 (0.41) NOS2NOS3DHFRALDH1A1KDM4E
SCHEMBL28182387 0.82 NOS2 (0.41) NOS2NOS3DHFRALDH1A1KDM4E
SCHEMBL21883590 0.81 TYR (0.45) NOS2ALDH1A1KDM4EMEN1MAPT
SCHEMBL19005863 0.80 NOS2 (0.42) NOS2NOS3DHFRALDH1A1KDM4E
SCHEMBL28009761 0.79 NOS2 (0.42) NOS2NOS3DHFRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597377-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597377-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 NOS2 1227/4885NOS3 887/4885DHFR 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.